MediMabBio won first place at Innovation Tiger 2025, a global biotech startup competition held at Shonan iPark in Japan. The final round featured 16 companies selected from 79 applicants across Korea, Japan, and Taiwan.
The event was jointly organized by major pharmaceutical and biotech companies, including MSD, Takeda, Eli Lilly, and Astellas, and evaluated participants based on technological innovation, commercialization potential, and partnership opportunities.
As the grand prize winner, MediMabBio received a ¥3,000,000 award and was invited to participate in the upcoming SHIC 2025 conference in Boston, which will serve as a valuable opportunity to meet global investors and potential partners.
During the competition, MediMabBio presented its AI-driven immunotherapy platform focused on both oncology and autoimmune diseases. CEO Kang Yu-Hoi commented, “Winning Innovation Tiger 2025 confirms recognition of our technology and growth potential. Through SHIC, we aim to strengthen global partnerships and accelerate investor engagement.”